Crossmark

Salvage dacomitinib plus intraventricular pemetrexed for leptomeningeal metastasis after failure of third‑generation EGFR‑TKIs in EGFR‑mutant NSCLC: an ambispective cohort study

Crossref DOI link: https://doi.org/10.1007/s11060-026-05544-0

Published Online: 2026-03-26

Published Print: 2026-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wang, Xiaoyue

Wen, Hua

Xie, Yuwen

Xu, Ting

Fang, Hehui

Liu, Na

Fang, Shencun
Funding

Funding for this research was provided by:

The Nanjing Technology Development Special Fund (ZKX24052)

The CSCO Fund—EGFR Mutant Non–Small Cell Lung Cancer Research Fund (Y-2024AZ(EGFR)MS-0101)
License Information

Text and Data Mining valid from 2026-03-26

Version of Record valid from 2026-03-26
More Information

Article History

Received: 13 February 2026

Accepted: 23 March 2026

First Online: 26 March 2026

Declarations

:

: The study was conducted in accordance with the ethical guidelines of the Declaration of Helsinki and was approved by the Ethics Committee of the Affiliated Brain Hospital of Nanjing Medical University (Approval Number: 2025-KY154-01).

: The authors declare no competing interests.

Document is current

Any future updates will be listed below